{"product_id":"mlpcare-bcg-matrix","title":"MLP Saglik Hizmetleri Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where MLP Saglik Hizmetleri’ products sit—Stars, Cash Cows, Dogs, or Question Marks? This snapshot hints at competitive strengths and cash flow risks, but the full BCG Matrix gives you quadrant-by-quadrant placement, data-backed recommendations, and clear strategic moves. Purchase the complete report for a ready-to-use Word analysis plus an Excel summary so you can present, decide, and act fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlagship tertiary hospitals (Liv)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFlagship tertiary hospitals (Liv) command a leading share in big-city private care, delivering brand-led outcomes and patient experience that sustain a 10–15% price premium over peers and EBITDA margins above 20%; heavy capex (around 7–9% of revenue in 2024) is absorbed by double-digit admission growth in metros (≈12% y\/y), so continue investing to cement leadership and set the price curve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and cardiac centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology and cardiac centers are complex, high-demand specialty lines with strong referral pull; WHO reported ~19.3 million new cancer cases in 2020 and cardiovascular disease remained the leading cause of death at ~17.9 million annually (2019), underscoring ongoing market growth as incidence and awareness rise. These programs drive a reputation flywheel and cross-sell, and command premium margins that justify funding technology and top clinicians to keep the edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobotic and complex surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRobotic and complex surgery shows rapid adoption and clear clinical differentiation, with global robot-assisted procedures exceeding 1 million annually and da Vinci–class systems costing ~2 million USD plus ~150–200k USD\/yr maintenance. High-ticket cases drive strong payer interest where studies report up to 20–30% fewer complications and shorter LOS, boosting revenue per case; utilization and surgeon throughput are climbing, supporting outcomes-focused marketing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced imaging networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced imaging networks are stars for MLP Saglik Hizmetleri: MRI\/CT\/PET now represent a high share of diagnostic revenue in key metros, with 2024 volumes up about 15% year‑on‑year and growing as elective care rebounds. They act as critical feeders to oncology and cardiology specialty lines. Cash in broadly matches cash out at this growth stage, so targeted capacity additions where scanners are bottlenecked and locking in corporate contracts are immediate priorities.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh metro share: MRI\/CT\/PET ≈ core diagnostic revenue\u003c\/li\u003e\n\u003cli\u003e2024 volumes: +15% YoY\u003c\/li\u003e\n\u003cli\u003eFeeds oncology\/cardiology pipelines\u003c\/li\u003e\n\u003cli\u003eCapex to remove bottlenecks\u003c\/li\u003e\n\u003cli\u003eLock corporate contracts to secure utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical tourism programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedical tourism programs are Stars: inbound demand to Turkey grew to over 1 million patients annually by 2023 and remains price-competitive, with procedures typically 30–50% cheaper than EU\/US peers; strong brand recognition across the Middle East and CIS drives high conversion but requires targeted marketing and coordination spend to scale. Double down on concierge pathways and partner funnels to capture higher-value cases and lift ancillary revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size: \u0026gt;1M patients (2023)\u003c\/li\u003e\n\u003cli\u003ePrice advantage: 30–50% vs EU\/US\u003c\/li\u003e\n\u003cli\u003eInvestment required: marketing \u0026amp; coordination to scale\u003c\/li\u003e\n\u003cli\u003eFocus: concierge services + partner funnels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlagship hospitals: \u003cstrong\u003e10-15%\u003c\/strong\u003e premium, EBITDA \u003cstrong\u003e\u0026gt;20%\u003c\/strong\u003e; metro admissions \u003cstrong\u003e+12%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFlagship tertiary hospitals: 10–15% price premium, EBITDA \u0026gt;20%, capex 7–9% revenue (2024); admissions +12% YoY in metros. Oncology\/cardiac centers: high-margin referral engines; oncology incidence rising (≈24M new cases projected 2024–25). Robotic surgery: \u0026gt;1M global procedures\/yr; system cost ≈2M USD. Medical tourism: \u0026gt;1M inbound patients (2023), price gap 30–50% vs EU\/US.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex % rev (flagship)\u003c\/td\u003e\n\u003ctd\u003e7–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetro admissions YoY\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlagship EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical tourism volume\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1M (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix for MLP Sağlık Hizmetleri: maps Stars, Cash Cows, Question Marks and Dogs with clear invest\/hold\/divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing MLP Saglik Hizmetleri units in clear quadrants for C-level decisions and quick PowerPoint export.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral inpatient care (Medical Park)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneral inpatient care at Medical Park is a mature, high-share service across the MLP network with stable volumes, standardized operations and strong margins; it requires low incremental promotional spend. It consistently generates operating cash to fund growth while management optimizes length-of-stay and bed mix to raise throughput. Focus remains on bed-turn efficiency and marginal revenue per occupied bed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutpatient clinics and diagnostics (basic)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOutpatient clinics and basic diagnostics hold a defensible local share with steady, routine demand and high throughput; in Turkey private healthcare market size was about USD 15 billion in 2024, supporting predictable reimbursements. Margins are dependable (industry EBITDA typically mid-teens), growth is limited, so focus on optimizing scheduling and utilization. Keep unit costs tight and harvest cash to fund higher-growth segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMaternity and pediatrics (routine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaternity and routine pediatrics serve as a steady community draw with high brand trust, typically generating consistent outpatient volumes and repeat visits; industry benchmarks in 2024 show continuity clinics often retain over 80% of families year-over-year. Growth is modest while patient churn remains low, supporting stable cashflow and EBITDA margin resilience. Ancillary pull-through from labs and imaging can add 15–25% incremental revenue per episode, improving unit economics. Focus on preserving patient experience and core clinical capacity while avoiding costly, low-return enhancements that dilute ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmergency departments (high-volume)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmergency departments (high-volume) deliver always-on access that cements market share across Turkey's ~85.3 million population (2024), producing a flat but reliable feeder stream; disciplined throughput and coding drive margins typically in the low double-digits when optimized. Focus on flow, case mix, and payer mix keeps cash positive despite limited growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAlways-on access: steady catchment\u003c\/li\u003e\n\u003cli\u003eMargins: low double-digits when throughput\/coding disciplined\u003c\/li\u003e\n\u003cli\u003eGrowth: flat but dependable feeder\u003c\/li\u003e\n\u003cli\u003ePriorities: flow, case mix, payer mix to maintain cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate check-ups and insurance panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMLP Sağlık Hizmetleri leverages a large installed base of corporate check-up and insurance-panel contracts, delivering repeatable, low-risk revenue that in 2024 accounted for a majority of outpatient admissions. These services are price-sensitive but require low incremental capex, enabling stable margins and cash generation. Focus is on maintaining relationships and incrementally upselling care pathways and preventive programs to existing clients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled base: sustained contract portfolio\u003c\/li\u003e\n\u003cli\u003eRevenue: high recurring share in 2024\u003c\/li\u003e\n\u003cli\u003eCapex: low incremental investment\u003c\/li\u003e\n\u003cli\u003eStrategy: relationship maintenance + upsell\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarvest steady cash: optimize throughput, utilization and upsell across Turkish clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMLP cash cows—general inpatient, outpatient diagnostics, maternity\/pediatrics, ED and corporate contracts—generate steady operating cash with EBITDA typically mid-teens for clinics and low double-digits for EDs in 2024, funding growth while needing low incremental capex. Volumes are stable across Turkey (pop. 85.3M) and private market ≈USD15B (2024); focus on throughput, utilization and upsell. Harvest cash, optimize unit economics, avoid low-return expansions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eService\u003c\/th\u003e\n\u003cth\u003e2024 share\u003c\/th\u003e\n\u003cth\u003eEBITDA\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003ePriority\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInpatient\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eMid‑teens\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eThroughput\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient\/Diagnostics\u003c\/td\u003e\n\u003ctd\u003eDefensible\u003c\/td\u003e\n\u003ctd\u003eMid‑teens\u003c\/td\u003e\n\u003ctd\u003eFlat\u003c\/td\u003e\n\u003ctd\u003eUtilization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaternity\/Pediatrics\u003c\/td\u003e\n\u003ctd\u003eStable\u003c\/td\u003e\n\u003ctd\u003eMid‑teens\u003c\/td\u003e\n\u003ctd\u003eModest\u003c\/td\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eED\u003c\/td\u003e\n\u003ctd\u003eFeeder\u003c\/td\u003e\n\u003ctd\u003eLow double‑digits\u003c\/td\u003e\n\u003ctd\u003eFlat\u003c\/td\u003e\n\u003ctd\u003eFlow\/Coding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate contracts\u003c\/td\u003e\n\u003ctd\u003eMajority outpatient\u003c\/td\u003e\n\u003ctd\u003eStable\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eUpsell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eMLP Saglik Hizmetleri BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the final MLP Sağlık Hizmetleri BCG Matrix you'll receive after purchase — no watermarks, no demo notes, just the polished strategic report. It maps products and services into Stars, Cash Cows, Question Marks and Dogs with clear visuals and actionable takeaways. The same editable, print-ready document is delivered instantly to your inbox. Use it in planning sessions, investor decks, or board meetings—no surprises, just clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674751353209,"sku":"mlpcare-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/mlpcare-bcg-matrix.png?v=1755794709","url":"https:\/\/portersfiveforce.com\/products\/mlpcare-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}